ArticleFrontiers in oncology2022

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.

Fortunato Morabito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.